SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare informs about company updates

17 Mar 2018 Evaluate

Shilpa Medicare has informed that the US FDA has issued an Establishment Inspection Report (EIR) for the Company’s formulations manufacturing facility (SEZ unit) located at Jadcherla, Telangana, India which was inspected between 11th November and 30th November 2017. FDA has determined that the inspection classification of this facility is VAI and accordingly EIR issued. They wish to confirm that earlier status of their formulation unit is maintained.

The above information is a part of company’s filings submitted to BSE.

 

Shilpa Medicare Share Price

411.55 0.30 (0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×